A peripartum cardiomyopathy case treated with bromocriptine

Year 2021, Volume: 3 Issue: Supplement 1 , 117 - 119 , 07.03.2021

Şeyda Günay , Osman Akın Serdar , Dilek Yeşilbursa , Sümeyye Güllülü , Naile Bolca Topal

https://doi.org/10.46310/tjim.868729

https://izlik.org/JA37HR74FG

Abstract

Introduction: Peripartum cardiomyopathy is a rare disease that is difficult to diagnose and treat. Clinical findings are similar with heart failure. New treatments are needed in addition to the treatment of heart failure.
Case Report: A 32-year-old woman presented with symptoms of heart failure 4 days after first delivery. Chest X-ray showed cardiomegaly. Serum BNP level was high. Transthoracic echocardiography (TTE) indicated dilated left atrium and left ventricle, severe mitral regurgitation and ventricular dysfunction. The global longitudinal strain was – 9.1%. Cardiac magnetic resonance imaging (MRI) revealed mid-myocardial staining detected in late phase images. Concomitant bromocriptine (2,5 mg po twice a day for 15 days and then 2,5 mg po once a day for 15 days) was used with standard heart failure therapy. At 6 months, TTE and cardiac MRI revealed normal biventricular function and size. Global longitudinal strain was –14%.
Conclusion: Patients with peripartum cardiomyopathy may benefit from bromocriptine.

Keywords

peripartum , heart , failure , cardiomyoathy , bromocriptine

References

• 1) Mubarik A, Chippa V, Iqbal AM. Postpartum Cardiomyopathy. [Updated 2020 Aug 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534770/)
• 2) Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000;283:1183-8.
• 3) Dinic V, Markovic D, Savic N, Kutlesic M, Jankovic RJ. Peripartum Cardiomyopathy in Intensive Care Unit. Front Med (Lausanne) 2016;3:18.
• 4) Ansari AA, Fett JD, Carraway RD, Mayne AE, Onlamoon M, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 2002;23:289-312.
• 5) Felker GM, Jaeger CJ, Klodas E, Thiemann DR, Hare JM, Hruban RH, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 2000;140:785-91.
• 6) Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughman KL. Peripartum myocarditis and cardiomyopathy.Circulation 1990;81:922-8.
• 7) Neligan JP, Laffey JG. Clinical review: Special populations- critical illness and pregnancy. Crit Care 2011;15:227.
• 8) Biteker M, Duran NE, Ozkan M. The role of bromocriptine in peripartum cardiomyopathy. Am J Obstet Gynecol 2009; 201:e13.
• 9) Elkayam U, Tummala PP, Rao K, Akhter MW, Karaalp IS, Wani OR, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001;344:1567-71.